Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
M Ventures
AI-generated illustration
OrganisationNL

M Ventures

Merck KGaA's corporate venture Arm; joined T-Therapeutics' $133m Series B in November 2026.

Last refreshed: 14 November 2026 · Appears in 1 active topic

Key Question

What does Germany's Merck gain from a stake in a Cambridge spinout?

Timeline for M Ventures

#17 5 Nov

Joined T-Therapeutics' Series B

UK Startups and Innovation: T-Therapeutics raises $133m in Series B
View full timeline →

Background

M Ventures, the corporate venture Arm of the German group Merck KGaA, joined T-Therapeutics' $133m Series B on 5 November 2026 as a new investor. Advent Life Sciences and the British Business Bank co-led the round, and Eli Lilly, Johnson & Johnson Innovation and Samsara BioCapital also joined.

M Ventures is based in Amsterdam and invests in healthcare, life Science and electronics companies for its parent, which is based in Darmstadt. It has no link to the American drugmaker Merck & Co.

The stake gives Merck KGaA an early view of T-cell receptor bispecifics, a class of drug that can reach proteins inside diseased cells.

Common Questions
Who owns M Ventures?
M Ventures is the corporate venture Arm of Merck KGaA, the German group based in Darmstadt. It is not linked to Merck & Co.Source: M Ventures
Which UK biotechs has M Ventures invested in?
M Ventures joined T-Therapeutics' $133m Series B in November 2026 as a new investor.Source: BioPharm International
Where is M Ventures based?
In Amsterdam. It invests for Merck KGaA, which is based in Darmstadt, Germany.Source: M Ventures
Source Material

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.